Zenas BioPharma details autoimmune drug pipeline at virtual R&D event
Zenas BioPharma will spotlight its late-stage autoimmune drug candidates and bring in outside clinical voices during a virtual R&D event on October 27, 2026.
Zenas BioPharma 1 article
Engineered protein therapeutics are central to Zenas BioPharma, an antibody and protein-therapeutics company associated with autoimmune disease therapeutics and obexelimab bifunctional antibody. A further layer of its biologics work includes B-cell activity inhibition without depletion and IgG4-related disease therapeutics, with CNS-penetrant BTK inhibition providing the disease, target or immune-mechanism context. For entity matching, binding format and drug molecule are separate from the organization; Zenas BioPharma is also associated with B-cell lineage immune modulation.